|
Post by matt on Nov 15, 2016 11:22:28 GMT -5
Need to get over the shorts -- not a long-term issue. China is a difficult market. If Mannkind can get in, great, but the best future markets are Canada, Europe, and Japan. China and Japan are both difficult markets. I spent five years living and working in Japan and I have lots of battle scars. The upside is that Japan has some good pricing, although the price will get knocked down on a regular schedule so the launch price is the best MNKD can ever achieve. They also have to be very careful if they enter Japan with a partner as most pharma companies there play hard ball. In any Asian market, the only thing that can happen quickly is failure. Japan is not a short term option unless by short term you mean a minimum of two years until market entry.
Canada and Europe are the best bets. EMA, for all their bureaucracy, it at least predictable. Don't expect pricing to be favorable except in a few northern countries and remember that Novo is Danish and Sanofi is French; both think that Europe belongs to them and will do all they can to keep it that way.
|
|
|
Post by BlueCat on Nov 15, 2016 12:53:43 GMT -5
Need to get over the shorts -- not a long-term issue. China is a difficult market. If Mannkind can get in, great, but the best future markets are Canada, Europe, and Japan. China and Japan are both difficult markets. I spent five years living and working in Japan and I have lots of battle scars. The upside is that Japan has some good pricing, although the price will get knocked down on a regular schedule so the launch price is the best MNKD can ever achieve. They also have to be very careful if they enter Japan with a partner as most pharma companies there play hard ball. In any Asian market, the only thing that can happen quickly is failure. Japan is not a short term option unless by short term you mean a minimum of two years until market entry.
Canada and Europe are the best bets. EMA, for all their bureaucracy, it at least predictable. Don't expect pricing to be favorable except in a few northern countries and remember that Novo is Danish and Sanofi is French; both think that Europe belongs to them and will do all they can to keep it that way.
Maybe this has already been covered somewhere on board - but would be nice if Amphastar would do in China what SNY was required, but didn't do in US. And in the process, Amphastar establishes an insulin put in the agreemeent to themselves. Essentially, it brings revenue (small percentage, but at larger volumes) to MNKD, but at lower shared mfg cost. It then allows MNKD to focus on Canada and EU. That would be sweet, and therefore, require more Afrezza ; )
|
|
|
Post by saxcmann on Nov 15, 2016 13:58:00 GMT -5
Mnkd should start inviting PCPs and endo nurses to afrezza speaking presentations. Not just prescribing endos! It will get the word out much faster and target more type 2s. Head endo nurses will provide info next day in office. Currently mnkd does not do this! Okay, I'm done ranting! Go mnkd!
PS...I need to start selling Afrezza. Can anyone get Mike in front of me? 😊
|
|
|
Post by sportsrancho on Nov 15, 2016 14:36:50 GMT -5
Mnkd should start inviting PCPs and endo nurses to afrezza speaking presentations. Not just prescribing endos! It will get the word out much faster and target more type 2s. Head endo nurses will provide info next day in office. Currently mnkd does not do this! Okay, I'm done ranting! Go mnkd! PS...I need to start selling Afrezza. Can anyone get Mike in front of me? 😊 Great point! It seems once someone starts on a path it's like pulling teeth getting them to change it, even if it's not working. Also maybe they listen to a speaker and go home and forget about it until someone asks them for a script. So they will have some back ground WHEN asked:-). Patients should be MNKD next focus!
|
|
|
Post by zuegirdor on Nov 15, 2016 17:03:57 GMT -5
Mnkd should start inviting PCPs and endo nurses to afrezza speaking presentations. Not just prescribing endos! It will get the word out much faster and target more type 2s. Head endo nurses will provide info next day in office. Currently mnkd does not do this! Okay, I'm done ranting! Go mnkd! PS...I need to start selling Afrezza. Can anyone get Mike in front of me? 😊 A Road Show! A campaign! What does it take to make it street legal?
|
|
|
Post by promann on Nov 15, 2016 17:19:15 GMT -5
Obviously they should keep focus on insurance coverage, better label, educating doctors, and then advertising to diabetics. We all know this and we also know we need cash so maybe sell rights of another drug in the pipe line or partner Afrezza in other countries. We have a good runway now and all we need to do is use it wisely and fly straight, go high throttle and lift off.
|
|
|
Post by letitride on Nov 15, 2016 21:24:00 GMT -5
Mnkd should start inviting PCPs and endo nurses to afrezza speaking presentations. Not just prescribing endos! It will get the word out much faster and target more type 2s. Head endo nurses will provide info next day in office. Currently mnkd does not do this! Okay, I'm done ranting! Go mnkd! PS...I need to start selling Afrezza. Can anyone get Mike in front of me? 😊 A Road Show! A campaign! What does it take to make it street legal? A road show was exactly what I had in mind. A significant part of an overall campaign. Street legal it already is . So its well past time to let everyone know it.
|
|
|
Post by audiomr on Nov 16, 2016 12:16:33 GMT -5
Need to get over the shorts -- not a long-term issue. China is a difficult market. If Mannkind can get in, great, but the best future markets are Canada, Europe, and Japan. China and Japan are both difficult markets. I spent five years living and working in Japan and I have lots of battle scars. The upside is that Japan has some good pricing, although the price will get knocked down on a regular schedule so the launch price is the best MNKD can ever achieve. They also have to be very careful if they enter Japan with a partner as most pharma companies there play hard ball. In any Asian market, the only thing that can happen quickly is failure. Japan is not a short term option unless by short term you mean a minimum of two years until market entry.
Canada and Europe are the best bets. EMA, for all their bureaucracy, it at least predictable. Don't expect pricing to be favorable except in a few northern countries and remember that Novo is Danish and Sanofi is French; both think that Europe belongs to them and will do all they can to keep it that way.
Agree. I do think Japan is more promising than China, though. And U.S. is the best market -- have to make it work here.
|
|
|
Post by sophie on Nov 16, 2016 14:03:51 GMT -5
It seems to me that keeping the business that we already have would be the cheapest and best way to improve cashflow. We lose far too much money to refills retention. Those are the people who already have a willing prescriber, a willing patient (probably), and a paying insurance (also maybe).
The biggest thing I want to see, and I'd imagine any partners would want to see, is demand for inhaled products. I'm sure Matt and Mike are working on figuring out what's causing this i.e. Mannkind Cares. If Afrezza is as amazing as we think, doctors will see improvement in Afrezza patients and possibly consider prescribing Afrezza for their other patients.
It still seems to me, as things stand right now, that we're still dependent on Afrezza sales if we want to develop as a company. Maybe Matt is finishing something else, but we still need Afrezza to start picking up the slack in the meantime, especially if we're going to use our remaining funds to promote it. That money needs to prove to be a good investment and return a good chunk or more back. It seems risky to allocate $20+ millions to possibly only return a few when you're strapped for cash. Afrezza needs to sell, and it needs to sell quickly.
Of course a partnership or milestone payments will lessen the urgency of this strategy.
|
|
|
Post by mockingjay on Nov 16, 2016 15:01:34 GMT -5
Mnkd should start inviting PCPs and endo nurses to afrezza speaking presentations. Not just prescribing endos! It will get the word out much faster and target more type 2s. Head endo nurses will provide info next day in office. Currently mnkd does not do this! Okay, I'm done ranting! Go mnkd! PS...I need to start selling Afrezza. Can anyone get Mike in front of me? 😊 you are kidding right , it's not that easy to invite them for your presentation, you can try to speak to them , they will turn away from you as quickly as you come . The only way that they will listen to you is you need to give them gifts (so they will talk to you), so it will cost a lot of money down the road
|
|